Missed Opportunities for Pharmacist Intervention Among Medicare Fee-for-Service Beneficiaries With Myasthenia Gravis: A Real-World Claims Analysis - Inovalon

Accepted for presentation at American Society of Health-System Pharmacists. Findings available upon request. Contact us for more information.

Previous PostPredictors of Timely Hypertension Treatment Escalation in the United States: Results from the Real-World BREAKTHROUGH Patient Registry
Next PostOutcomes of Inpatient and Outpatient Chimeric Antigen Receptor T-Cell Therapy in Newly Authorized Treatment Centers in the United States